Oral antibiotics for community–acquired pneumonia with chest-indrawing in children aged below five years: A Systematic Review

Video based non-contact monitoring of respiratory rate and chest indrawing in children with pneumonia

OBJECTIVE

Pneumonia is the single largest cause of death in children worldwide due to infectious diseases. According to WHO guidelines, fast breathing and chest indrawing are the key indicators of pneumonia in children requiring antibiotic treatments. The aim of this study was to develop a video-based novel method for simultaneous monitoring of respiratory rate and chest indrawing without upsetting babies.

APPROACH

Respiratory signals, corresponding to periodic movements of chest-abdominal walls during breathing, were extracted by analyzing RGB (red, green, blue) components in video frames captured by a smartphone camera. Respiratory rate was then obtained by applying fast fourier transform on the de-noised respiratory signal. Chest indrawing was detected by analysing relative phases of regional chest-abdominal wall mobility. The performance of the developed algorithm was evaluated on both healthy and pneumonia children.

MAIN RESULTS

The proposed method can measure respiratory rate with an overall mean absolute error of 1.8 bpm in the range 18-105 bpm. Phase difference between regional chest wall movements in the chest indrawing (pneumonia) cases was found to be 143±23.9 degrees, which was significantly higher than that in the healthy cases 52.3 ±32.6 degrees (p<0.001).

SIGNIFICANCE

Being non-intrusive and non-subjective, this computer-aided method can be useful in the monitoring for respiratory rate and chest indrawing for the diagnosis of pneumonia and its severity in children.

[Effects of an In-House Antibiotic Stewardship Initiative on Diagnosis and Management of Community-Acquired Pneumonia in Childhood and Adolescence]

BACKGROUND

 Pediatric community-acquired pneumonia (pCAP) often leads to prescription of antibiotics and hospital admission of children. Unfortunately, adherence to diagnosis and treatment guidelines is inconsistent, and misuse of antibiotics may occur. Antimicrobial stewardship interventions, which were started in many hospitals during the last decade, can optimize management of pCAP without negative patient outcomes.

OBJECTIVES

 The objective of this retrospective analysis was to assess the influence of a newly implemented in-house pediatric antibiotic stewardship (ABS) initiative on guideline adherence and treatment quality.

MATERIALS AND METHODS

 Retrospective, patients' file-based analysis of the effects of an ABS initiative in a pediatric university hospital from January 2017 until March 2020. ABS initiative included creation of a local pCAP guideline for hospitalized children aged 90 days - 18 years, periodic training and continuous ABS support.

RESULTS

 A total of 230 patients with pCAP were included (145 before and 85 after intervention). Implementation of the ABS program led to reduction of antibiotics prescription without clear indication from 26 % to 10 % (p < 0.05). The inappropriate use of antibiotics decreased from 64 % to 27 % (p < 0.05), the rate of incorrect doses declined from 17 % to 10 % (p < 0.05) and the mean duration of antibiotic treatment declined from 10 to 7 days (p < 0.05). There were no differences between the two groups regarding length of stay, treatment failure or readmissions for respiratory infection.

CONCLUSIONS

 Pediatric antibiotic stewardship is an appropriate and safe method, and is beneficial to hospitalized patients with pCAP. Application of ABS programs may increase adherence to clinical guidelines and improve appropriate antimicrobial use without negative impact on patient outcomes. Multicenter follow-up studies are needed to clarify long-term effects of ABS programs.

Recommendations and guidelines for the treatment of pneumonia in Taiwan

Pneumonia is a leading cause of death worldwide, ranking third both globally and in Taiwan. This guideline was prepared by the 2017 Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group, formed under the auspices of the Infectious Diseases Society of Taiwan (IDST). A consensus meeting was held jointly by the IDST, Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM), the Medical Foundation in Memory of Dr. Deh-Lin Cheng, the Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education and CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines. The final guideline was endorsed by the IDST and TSPCCM. The major differences between this guideline and the 2007 version include the following: the use of GRADE methodology for the evaluation of available evidence whenever applicable, the specific inclusion of healthcare-associated pneumonia as a category due to the unique medical system in Taiwan and inclusion of recommendations for treatment of pediatric pneumonia. This guideline includes the epidemiology and recommendations of antimicrobial treatment of community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, healthcare-associated pneumonia in adults and pediatric pneumonia.

Antimicrobial Therapy in Community-Acquired Pneumonia in Children

PURPOSE OF REVIEW

Empirical antibiotic therapy remains the cornerstone of treatment in community-acquired pneumonia (CAP). However, the best option for empirical antibiotics for treatment on an ambulatory basis, as well as in those requiring hospitalization, is still unclear. This review tries to answer the question regarding the most appropriate antibiotics in different settings in children with CAP as well as duration of therapy.

RECENT FINDINGS

Recent studies have provided insights regarding use of oral antibiotics in children with mild to moderate CAP, and severe CAP with lower chest retractions but no hypoxia. In view of rapidly emerging resistance among various causative pathogens, several new drugs have been currently approved, or are under trial for CAP in children. Current knowledge suggests that the choice of antibiotics for ambulatory treatment of CAP is oral amoxicillin with a duration of 3-5 days. Children with CAP with lower chest retractions but no hypoxia can be treated with oral amoxicillin. Severe pneumonia can be treated with intravenous antibiotics consisting of penicillin/ampicillin with or without an aminoglycoside. Several new drugs have been developed and approved for use in CAP caused by multidrug-resistant organisms, but these should be used judiciously to avoid emergence of further resistance. Future research is needed regarding the safety and efficacy of newer drugs in children.